Egyesült Királyság - angol - MHRA (Medicines & Healthcare Products Regulatory Agency)

a a h pharmaceuticals ltd - rifampicin - oral capsule - 150mg

Egyesült Királyság - angol - MHRA (Medicines & Healthcare Products Regulatory Agency)

viatris uk healthcare ltd - rifampicin - oral capsule - 150mg

Egyesült Királyság - angol - MHRA (Medicines & Healthcare Products Regulatory Agency)

kent pharma (uk) ltd - rifampicin - oral capsule - 150mg

Egyesült Királyság - angol - MHRA (Medicines & Healthcare Products Regulatory Agency)

alliance healthcare (distribution) ltd - rifampicin - oral capsule - 150mg

Egyesült Királyság - angol - MHRA (Medicines & Healthcare Products Regulatory Agency)

de pharmaceuticals - rifampicin - oral capsule - 150mg

Egyesült Királyság - angol - MHRA (Medicines & Healthcare Products Regulatory Agency)

sigma pharmaceuticals plc - rifampicin - oral capsule - 300mg

Egyesült Királyság - angol - MHRA (Medicines & Healthcare Products Regulatory Agency)

sigma pharmaceuticals plc - rifampicin - oral capsule - 300mg

Egyesült Királyság - angol - MHRA (Medicines & Healthcare Products Regulatory Agency)

waymade healthcare plc - rifampicin - oral capsule - 150mg

Egyesült Királyság - angol - MHRA (Medicines & Healthcare Products Regulatory Agency)

de pharmaceuticals - rifampicin - oral capsule - 300mg

Ausztrália - angol - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - rifampicin, quantity: 20 mg/ml - oral liquid - excipient ingredients: agar; sucrose; methyl hydroxybenzoate; propyl hydroxybenzoate; potassium sorbate; saccharin; polysorbate 80; diethanolamine; purified water; sodium metabisulfite; fragrance (perfume) - tuberculosis. in the initial treatment and in re-treatment of patients with tuberculosis, rifadin must be used in conjunction with at least one other antituberculosis drug. leprosy. in the management of lepromatous leprosy and dimorphous leprosy to effect speedy conversion of the infectious state to the noninfectious state, which may be expected to occur in 3 to 4 months of treatment. as an alterantive drug in lepromatous, dimorphous, indeterminate and tuberculoid leprosy resistant to sulfones and other antileprosy drugs. as an alternative drug in all those patients having true drug allergy to the more commonly used antileprosy drugs. meningococcal disease. prophylaxis of meningococcal disease in close contacts of known cases and in carriers. (rifadin is not indicated for the treatment of meningococcal infections). haemophilus influenzae. prophylaxis of household contacts of patients with h. influenzae type b.